U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07904026) titled 'Testosterone-Informed De-Escalation in Metastatic Prostate Cancer (TIDE PC)' on Oct. 12.
Brief Summary: The purpose of this study is to use androgen deprivation therapy (ADT) intermittently in hopes of reducing side effects from ADT and reducing unnecessary dosing of ADT in adult men with a prolonged response to frontline therapy for metastatic hormone-sensitive prostate cancer (mHSPC). The primary aim is to determine the cumulative incidence of participants who experience prostate-specific antigen (PSA) relapse, clinical relapse, or death in the 18-month trial period.
The study will investigate the effects of holding (stopping and...